Spasticity drugs market seen topping $5.5 billion by 2030

The global market for spasticity management drugs is projected to rise from $3.99 billion in 2025 to $4.26 billion in 2026, according to a new report from The Business Research Company. The report points to rising neurological disease rates, aging populations and expanding rehab infrastructure as the main demand drivers, with North America leading today and Asia-Pacific expected to grow fastest.

Why it matters: - Spasticity management drugs are used to reduce muscle stiffness and spasms caused by neurological conditions such as stroke, cerebral palsy and multiple sclerosis. - The market’s growth tracks broader demand for neurological care, rehabilitation and mobility-focused treatment. - The forecast points to more spending on less invasive therapies, botulinum toxin treatments and precision medicine approaches.

What happened: - The Business Research Company published its Spasticity Management Drugs Market Report 2026 on July 22, 2026. - The report projects the market will grow from $3.99 billion in 2025 to $4.26 billion in 2026, a 6.8% compound annual growth rate. - The market is forecast to reach $5.58 billion by 2030, implying a 7.0% CAGR from 2026 to 2030. - North America held the largest regional share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - The report ties near-term growth to rising rates of neurological disorders, the limitations of traditional muscle relaxants, an aging population with mobility challenges, greater awareness of rehabilitative medicine and broader use of neurology-focused hospital care. - Longer-term growth is linked to targeted neuro-modulating drugs, wider use of botulinum toxin therapies, demand for less invasive treatments, precision medicine in neurology and expansion of rehabilitation-centered healthcare infrastructure. - Neurological disorders affect the brain, spinal cord and nervous system and can cause muscle rigidity, spasms, impaired movement and loss of motor coordination. - The Alzheimer’s Association reported in March 2024 that about 6.9 million Americans age 65 and older were living with Alzheimer’s disease, up from 6.7 million in 2023. - The American Health Care Association said in May 2023 that the U.S. had 6,129 hospitals, up 0.591% from 6,093 the year before. - The report says new strategic additions in the 2026 edition include market attractiveness scoring, TAM analysis, a company scoring matrix, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - The Business Research Company says it offers more than 30,000 reports across 27 industries and 60+ geographies, supported by 1,500,000 datasets and its Global Market Model platform. - A free sample is available here, and the full report is available here.

Between the lines: - The report frames spasticity treatment as part of a larger shift toward chronic neurological care rather than a narrow drug category. - North America’s lead suggests mature access to specialty care and advanced therapies, while Asia-Pacific growth points to catch-up demand as healthcare access broadens. - The emphasis on infrastructure and rehabilitation indicates the market depends on more than drug innovation alone.

What’s next: - The market is set to keep expanding through 2030 if neurological disease prevalence, aging demographics and rehab investment continue on their current path. - Demand should rise for therapies that are easier to use, more targeted and better integrated into long-term care. - The company’s updated forecasting tools and scoring models are aimed at helping buyers and suppliers identify the most attractive market segments.

The bottom line: - Spasticity drugs are moving from a niche treatment category toward a steadier growth market tied to rising neurological care needs worldwide.